Individualising therapy using individual participant data

The Lancet Psychiatry

Volumn 4, Issue 11, 2017, Pages 823-824

  Malhi, Gin S ^a,b  

^a ROYAL NORTH SHORE HOSPITAL   (Australia)

^b UNIVERSITY OF SYDNEY   (Australia)

Author keywords

[No Author keywords available]

Indexed keywords

OLANZAPINE; PLACEBO;

BIPOLAR I DISORDER; COMMUNITY CARE; DISEASE SEVERITY; DRUG EFFICACY; ECOLOGICAL FALLACY; HOSPITAL ADMISSION; HUMAN; MANIA; NOTE; PERSONALIZED MEDICINE; PRACTICE GUIDELINE; PRIORITY JOURNAL; SYMPTOM; YOUNG MANIA RATING SCALE; BIPOLAR DISORDER;

BIPOLAR DISORDER; HUMANS; OLANZAPINE;

EID: 85029585712     PISSN: 22150366     EISSN: 22150374     Source Type: Journal    
DOI: 10.1016/S2215-0366(17)30370-X     Document Type: Note

References (5)

1. Malhi, GS, Bassett, D, Boyce, P, et al. Royal Australian and New Zealand College of Psychiatrists clinical practice guidelines for mood disorders. Aust NZ J Psychiatry 49 (2015), 1087–1206.
2. Goodwin, GM, Haddad, PM, Ferrier, IN, et al. Evidence-based guidelines for treating bipolar disorder: Revised third edition recommendations from the British Association for Psychopharmacology. J Psychopharmacol 30 (2016), 495–553.
3. Tohen, M, Chengappa, RK, Suppes, T, et al. Relapse prevention in bipolar I disorder: 18-month comparison of olanzapine plus mood stabiliser v mood stabiliser alone. Br J Psychiatry 184 (2004), 337–345.
4. Samara, MT, Goldberg, Y, Levine, SZ, et al. IInitial symptom severity of bipolar I disorder and the efficacy of olanzapine: a meta-analysis of individual participant data from five placebo-controlled studies. Lancet Psychiatry, 2017 published online Sept 19. http://dx.doi.org/10.1016/S2215-0366(17)30331-0.
5. Malhi, G, Morris, G, Hamilton, A, Outhred, T, Das, P, Defining the role of SGAs in the long-term treatment of bipolar disorder. Bipolar Disord 9 (2017), 65–67.